Repros Therapeutics up 5% After FDA Provides Guidance on clinical Hold of Proellex

Repros Therapeutics (NASDAQ: RPRX) is trading higher on the session after announcing that the FDA provides guidance for the conduct of a phase 2 study of low dose oral Proellex. The FDA said it has agreed to update the full clinical hold to a partial clinical hold once they have reached agreement with Repros on the design of a Phase 2 study protocol.

Joseph Podolski, President and CEO of Repros stated, "We appreciate the timely review of our safety analysis by the FDA and are pleased with the guidance that they provided. We agreed with their suggestions on the design of the study and plan to commence the Phase 2 study as soon as possible."

Repros Therapeutics is currently trading at $8.47, a gain of $0.39 or 4.83%.

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.